Safety of long-term isoniazid preventive therapy in children with HIV: A comparison of two dosing schedules

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 1, 2013, Pages

  Le Roux, Stanzi M ^a   Cotton, M F ^b   Myer, L ^a   Le Roux, D M ^a   Schaaf, H S ^b   Lombard, C J ^c   Zar, H J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Africa; AIDS; Prophylaxis; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN;

ABDOMINAL TUBERCULOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SOUTH AFRICA; TOXIC HEPATITIS; TUBERCULOSIS; VIRUS HEPATITIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; ISONIAZID; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUBERCULOSIS;

EID: 84871221818     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0820     Document Type: Article

References (35)

1. World Health Organization. Three I's meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Report of a Joint World Health Organization HIV/AIDS and TB Department Meeting. Geneva, Switzerland: WHO, 2008. http://www.who.int/hiv/ pub/meetingreports/WHO-3Is-meeting-report.pdf Accessed September 2012.
2. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. Geneva, Switzerland: WHO, 2010. http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html Accessed September 2012.
3. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/9789241500708-eng.pdf Accessed September 2012.
4. Donald P R. Anti-tuberculosis drug-induced hepatotoxicity in children. Pediatr Rep 2011; 3: e16.
5. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489-499. (Pubitemid 40861991)
6. Lee W M. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485. (Pubitemid 36910027)
7. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for a ntituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
8. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
9. Tedla Z, Nyirenda S, Peeler C, et al. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-infected adults in Botswana. Am J Respir Crit Care Med 2010; 182: 278-285.
10. Kopanoff D E, Snider D E Jr, Caras G J. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001. (Pubitemid 8380195)
11. LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-447. (Pubitemid 37046873)
12. Steele M A, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
13. Martinson N A, Barnes G L, Moulton L H, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20.
14. Wu S S, Chao C S, Vargas J H, et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 2007; 84: 173-179. (Pubitemid 47205750)
15. Beaudry P H, Brickman H F, Wise M B, MacDougall D. Liver enzyme disturbances during isoniazid chemoprophylaxis in children. Am Rev Respir Dis 1974; 110: 581-584.
16. Nemir R L, O'Hare D. Tuberculosis in children 10 years of age and younger: three decades of experience during the chemotherapeutic era. Pediatrics 1991; 88: 236-241.
17. Palusci V J, O'Hare D, Lawrence R M. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr Infect Dis J 1995; 14: 144-148.
18. Gray D, Nuttall J, Lombard C, et al. Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis. J Trop Pediatr 2009; 56: 159-165.
19. Madhi S A, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365: 21-31.
20. Samandari T, Agizew T B, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
21. Zar H J, Cotton M F, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334: 136.
22. Zar H J, Workman L, le Roux S M, et al. A randomized controlled trial of intermittent compared with daily cotrimoxazole preventive therapy in HIV-infected children. AIDS 2010; 24: 2225-2232.
23. National Institutes of Health. Division of AIDS (DAIDS) revised toxicity tables for grading severity of pediatric adverse experiences. US National Institutes of Health DAIDS HIV Vaccine and Research Program, version 1.0. Bethesda, MD, USA: NIH, 2004. http://www3.niaid.nih.gov/LabsAndResources/ resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf Accessed September 2012.
24. le Roux S M, Cotton M F, Golub J E, le Roux D M, Workman L, Zar H J. Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. BMC Med 2009; 7: 67.
25. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330. (Pubitemid 23333873)
26. Garcia-Cortes M, Stephens C, Lucena M I, Fernandez-Castaner A, Andrade R J. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011; 55: 683-691.
27. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-310. (Pubitemid 32016915)
28. Maria V A, Victorino R M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-669. (Pubitemid 27392358)
29. Frigati L J, Kranzer K, Cotton M F, Schaaf H S, Lombard C J, Zar H J. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax 2011; 66: 496-501.
30. Jacobsen K H, Wiersma S T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28: 6653-6657.
31. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002; 2: 293-302. (Pubitemid 34464740)
32. Kumar A, Misra P K, Mehotra R, Govil Y C, Rana G S. Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis? Am Rev Respir Dis 1991; 143: 1350-1352.
33. Ohkawa K, Hashiguchi M, Ohno K, et al. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002; 72: 220-226. (Pubitemid 35034500)
34. Bhadauria S, Mishra R, Kanchan R, et al. Isoniazid-induced apoptosis in HepG2 cells: generation of oxidative stress and Bcl-2 down-regulation. Toxicol Mech Methods 2010; 20: 242-251.
35. Zhu R, Kiser J J, Seifart H I, et al. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV-exposed infants receiving isoniazid. J Clin Pharmacol 2012; 52: 511-519.